Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics - PubMed (original) (raw)
Daniel D Buchanan, Melissa Barker, Lesley Jaskowski, Michael D Walsh, Genevieve Birney, Michael O Woods, John L Hopper, Mark A Jenkins, Melissa A Brown, Sean V Tavtigian, David E Goldgar, Joanne P Young, Amanda B Spurdle
Affiliations
- PMID: 19267393
- PMCID: PMC2707453
- DOI: 10.1002/humu.20936
Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics
Sven Arnold et al. Hum Mutat. 2009 May.
Abstract
Reliable methods for predicting functional consequences of variants in disease genes would be beneficial in the clinical setting. This study was undertaken to predict, and confirm in vitro, splicing aberrations associated with mismatch repair (MMR) variants identified in familial colon cancer patients. Six programs were used to predict the effect of 13 MLH1 and 6 MSH2 gene variants on pre-mRNA splicing. mRNA from cycloheximide-treated lymphoblastoid cell lines of variant carriers was screened for splicing aberrations. Tumors of variant carriers were tested for microsatellite instability and MMR protein expression. Variant segregation in families was assessed using Bayes factor causality analysis. Amino acid alterations were examined for evolutionary conservation and physicochemical properties. Splicing aberrations were detected for 10 variants, including a frameshift as a minor cDNA product, and altered ratio of known alternate splice products. Loss of splice sites was well predicted by splice-site prediction programs SpliceSiteFinder (90%) and NNSPLICE (90%), but consequence of splice site loss was less accurately predicted. No aberrations correlated with ESE predictions for the nine exonic variants studied. Seven of eight missense variants had normal splicing (88%), but only one was a substitution considered neutral from evolutionary/physicochemical analysis. Combined with information from tumor and segregation analysis, and literature review, 16 of 19 variants were considered clinically relevant. Bioinformatic tools for prediction of splicing aberrations need improvement before use without supporting studies to assess variant pathogenicity. Classification of mismatch repair gene variants is assisted by a comprehensive approach that includes in vitro, tumor pathology, clinical, and evolutionary conservation data.
Copyright 2009 Wiley-Liss, Inc.
Figures
Figure 1
PCR amplification of LCL-derived cDNA from variant carriers a. The target amplicon incorporates c.-28 (5'UTR) to c.1426 of MLH1. Lanes A (variant MSH2 c.913G>A) and D (variant MLH1 c.1668-1G>A) display normal wildtype product, with two additional fainter products representing native alternately-spliced mRNA (exon 9 exclusion, exon 9 and 10 exclusion). Lane B (variant MLH1 c.116+5G>C) shows the inclusion of 227bp (uppermost product, Arrow 1) and a concatenated wildtype/variant product (above wildtype product). Lane C (variant MLH1 c.208-3C>G) shows the exclusion of exon 3 (Arrow 2) overlying the native exon 9 exclusion product. b. The target amplicon incorporates c.441 to c.1054 of MLH1. Lanes A (variant MSH2 c.571_573delCTC), B (variant MSH2 c.942+3A>T) and D (variant MSH2 c.913G>A) display normal wildtype product, with fainter product (Arrow 1) comprising a concatenation of wildtype and native alternately-spliced mRNA excluding exon 9. Lane C (variant MLH1 c.790+2_+3insT) shows increased concatenation of wildtype and exon 9 exclusion (Arrow 1, Lane C). Genotyping for the presence of an in cis 655A>G polymorphism in exon 8 confirmed that no wildtype mRNA expressed by the variant allele, and that all normal length mRNA in both upper bands (Arrows 1 and 2, Lane C) was derived from the wildtype allele. The product indicated by Arrow 3 comprises variant-derived product exclusive of exon 9, and that indicated by Arrow 4 comprises a variant-derived product exclusive of both exons 9 and 10. c. The target amplicon incorporates c.1392 to c.1912 of MLH1. Lanes A (variant MSH2 c.1906G>A), C (variant MSH2 c.942+3A>T) and D (variant MSH2 c.913G>A) display normal wildtype band weights. In lane B (variant MLH1 c.1668-1G>A), the band indicated by Arrow 1 comprises a concatenation of wildtype and exon 15 exclusion products, while the product indicated by Arrow 2 comprises exon 15 exclusion only. d. The target amplicon incorporates c.1392 to c.2278 of MLH1. Lanes A (variant MSH2 c.913G>A), B (variant MSH2 c.1865C>T) and D (variant MSH2 c.1906G>C) display normal wildtype product. In lane B (variant MLH1 c.1732-1G>A), the band indicated by Arrow 1 comprises a concatenation of wildtype and exon 16 exclusion products, while the band indicated by Arrow 2 comprises a exon 16 exclusion product only. e. The target amplicon incorporates c.1781 to c.2278 of MLH1. Lanes A (variant MSH2 c.1865C>T), B (variant MSH2 c.1906G>C) and D (variant MSH2 c.571_573delCTC) display normal wildtype products. In lane C (variant MLH1 c.1990-1 g>A) the band indicated by Arrow 1 comprises a concatenation of wildtype and exon 18 exclusion product, while Arrow 2 comprises the exon 18 exclusion product only. f. The target amplicon incorporates c.627 to c.1296 of MSH2. Lanes A (variant MLH1 c.1732-1G>A), B (variant MLH1 c.208-3C>G) and D (variant MLH1 c.116+5G>C) display normal wildtype products. In lane C (variant MSH2 c.942+3A>T), the band indicated by Arrow 1 comprises a concatenation of wildtype and exon 5 exclusion product, while the band indicated by Arrow 2 comprises the exon 5 exclusion product only.
Similar articles
- Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants.
Pagenstecher C, Wehner M, Friedl W, Rahner N, Aretz S, Friedrichs N, Sengteller M, Henn W, Buettner R, Propping P, Mangold E. Pagenstecher C, et al. Hum Genet. 2006 Mar;119(1-2):9-22. doi: 10.1007/s00439-005-0107-8. Epub 2005 Dec 8. Hum Genet. 2006. PMID: 16341550 - Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing.
Auclair J, Busine MP, Navarro C, Ruano E, Montmain G, Desseigne F, Saurin JC, Lasset C, Bonadona V, Giraud S, Puisieux A, Wang Q. Auclair J, et al. Hum Mutat. 2006 Feb;27(2):145-54. doi: 10.1002/humu.20280. Hum Mutat. 2006. PMID: 16395668 - A large fraction of unclassified variants of the mismatch repair genes MLH1 and MSH2 is associated with splicing defects.
Tournier I, Vezain M, Martins A, Charbonnier F, Baert-Desurmont S, Olschwang S, Wang Q, Buisine MP, Soret J, Tazi J, Frébourg T, Tosi M. Tournier I, et al. Hum Mutat. 2008 Dec;29(12):1412-24. doi: 10.1002/humu.20796. Hum Mutat. 2008. PMID: 18561205 - A review of mismatch repair gene transcripts: issues for interpretation of mRNA splicing assays.
Thompson BA, Martins A, Spurdle AB. Thompson BA, et al. Clin Genet. 2015 Feb;87(2):100-8. doi: 10.1111/cge.12450. Epub 2014 Jul 26. Clin Genet. 2015. PMID: 24989436 Review. - The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome.
Lucci-Cordisco E, Boccuto L, Neri G, Genuardi M. Lucci-Cordisco E, et al. Cancer Biomark. 2006;2(1-2):11-27. doi: 10.3233/cbm-2006-21-203. Cancer Biomark. 2006. PMID: 17192056 Review.
Cited by
- Detection Rate and Spectrum of Pathogenic Variations in a Cohort of 83 Patients with Suspected Hereditary Risk of Kidney Cancer.
Ouedraogo ZG, Ceruti F, Lepage M, Gay-Bellile M, Uhrhammer N, Ponelle-Chachuat F, Bidet Y, Privat M, Cavaillé M. Ouedraogo ZG, et al. Genes (Basel). 2023 Oct 25;14(11):1991. doi: 10.3390/genes14111991. Genes (Basel). 2023. PMID: 38002934 Free PMC article. - Left-sided colorectal cancer distinct in indigenous African patients compared to other ethnic groups in South Africa.
McCabe M, Penny C, Magangane P, Mirza S, Perner Y. McCabe M, et al. BMC Cancer. 2022 Oct 24;22(1):1089. doi: 10.1186/s12885-022-10185-3. BMC Cancer. 2022. PMID: 36280820 Free PMC article. - MLH1 Exon 12 Gene Deletion Leading to Lynch Syndrome: A Case Report.
Cui S, Zhang X, Zou R, Ye F, Wang Y, Sun J. Cui S, et al. Oncol Res Treat. 2021;44(7-8):414-421. doi: 10.1159/000516659. Epub 2021 Jun 4. Oncol Res Treat. 2021. PMID: 34091457 Free PMC article. - Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation.
von Salomé J, Liu T, Keihäs M, Morak M, Holinski-Feder E, Berry IR, Moilanen JS, Baert-Desurmont S, Lindblom A, Lagerstedt-Robinson K. von Salomé J, et al. Fam Cancer. 2018 Oct;17(4):531-537. doi: 10.1007/s10689-017-0067-x. Fam Cancer. 2018. PMID: 29288294 Free PMC article. - Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.
Yamaguchi-Kabata Y, Yasuda J, Tanabe O, Suzuki Y, Kawame H, Fuse N, Nagasaki M, Kawai Y, Kojima K, Katsuoka F, Saito S, Danjoh I, Motoike IN, Yamashita R, Koshiba S, Saigusa D, Tamiya G, Kure S, Yaegashi N, Kawaguchi Y, Nagami F, Kuriyama S, Sugawara J, Minegishi N, Hozawa A, Ogishima S, Kiyomoto H, Takai-Igarashi T; ToMMo Study Group; Kinoshita K, Yamamoto M. Yamaguchi-Kabata Y, et al. J Hum Genet. 2018 Feb;63(2):213-230. doi: 10.1038/s10038-017-0347-1. Epub 2017 Dec 1. J Hum Genet. 2018. PMID: 29192238 Clinical Trial.
References
- Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, Moslein G, Schulmann K, Propping P, Friedl W. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat. 2004;24(5):370–80. - PubMed
- Auclair J, Busine MP, Navarro C, Ruano E, Montmain G, Desseigne F, Saurin JC, Lasset C, Bonadona V, Giraud S, et al. Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat. 2006;27(2):145–54. - PubMed
- Caldes T, Godino J, Sanchez A, Corbacho C, De la Hoya M, Lopez Asenjo J, Saez C, Sanz J, Benito M, Ramon YCS, et al. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer. Oncol Rep. 2004;12(3):621–9. - PubMed
- Cartegni L, Krainer AR. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet. 2002;30(4):377–84. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources